Icon

STIVARGA - (40 mg; Tablet, Oral)

REGORAFENIB Bayer
40 mg; Tablet, Oral
Less Than $1000 mn
Less Than 5
Less Than 5
Less Than 5
None
None None
Indicated for the treatment of patients with metastatic colorectal cancer (CRC) who have been previously treated with fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy, an anti-VEGF therapy, and, if KRAS wild type, an anti-EGFR therapy.
Yes
****** & **** *** *** ***** ** **** **** ** **** ******* ********* (**** **, ****), ******* (*** **, ****), ******* (*** *, ****) *** ******* (*** *, ****) ** ******* *** **** ************ *********. *** *** ******* ** *** **, ****. ***** ***** * **** ******* ****** *** *** ***** ****** ****** '*** (**** *, ****). ****** *** ****** ** ** ****** **** ********** *** ********* **** **** ***** *** ***** ** ********* *** *** *****. *****, ***** ******* **** ******, ***** *** ***** ** ********** *** *** *****. ******** ****** ***** * **** *********** *** *** ** ****** ********* (*** **, ****) ** ****** **** ****** *********** *** ***** ** *** ****** ** **** *** *********** ** ***.
STIVARGA Patent 1 Patent 2 Patent 3 Patent 4 Patent 5
**** ******* ******* ******* ******* *******
****** ******* ******* ******* ******* *******
Company FTF Status / 180 days exclusivity 30-Months stay Current Litigation Status Current Approval Status Likelihood of launch
**** *** \ ********* **** **, **** ******* **** ***** **** ****(***** ******)
****** *** \ ********* **** **, **** ******* **** ***** **** ****(***** ******)
  1. *** *, **** : ****** ******** ***** ********* *** **** ** ****** ******* ********* (*** **, ****) ** ******.
  2. *** **, **** : **** ******** ***** ********* ****** **** ** ******* ********* (*** **, ****), ******* (*** **, ****), ******* (*** *, ****) *** ******* (*** *, ****) ** *******.
  3. *** **, **** : ***** **** ****** *** **** ** ** ** ********.
  4. *** *, **** : ******** *** *** ****** ** **** ** *********** ** *** ** ********* (*** **, ****) ** ****** **** ****** *********** ***.
  5. *** *, **** : ****** ******** ***** ********* **** ** ******* ********* (*** *, ****) ** ******.
  6. *** **, **** : ***** **** ****** ** ** ** ********.
  7. *** **, **** : * *** ****** '*** (**** *, ****) *** ****** ** *****.
  8. *** **, **** : ***** ***** * **** ******* ****** *** *** ***** ****** ****** '*** (**** *, ****).
  9. *** **, **** : ***** ******* **** ****, ***** *** ***** ** ********** *** *** *****.
  10. *** **, **** : ********** ********* **** ****** ** ****** '*** (**** *, ****).
  11. *** **, **** : ***** ******* **** ******, ***** *** ***** ** ********** *** *** *****.

Download ParaIV Report


Download ParaIV Detailed Report


To get detailed report Contact Us

ParaIV Advanced Search






Please contact contact@researchdelta.com to get more details.